Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Mike A CornejoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.
Zachary V SamuelsDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.ORCID 0000-0001-6639-5402
Gina DehlaviDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.
Lukas CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Wei-Siang Mark KaoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.
Emilia StrugalaDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.
Brian M ZeglisDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.ORCID 0000-0002-9091-744X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerR01CA281801 · NCI · FRED HUTCHINSON CANCER CENTER · PI Delphine L Chen, PAUL D. LAMPE · 2023 to 2026
$2.4M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
The Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell TumorR21CA309945 · NCI · HUNTER COLLEGE · PI Filemon S Dela Cruz, Brian Matthew Zeglis · 2026 to 2026
In vivo pretargeting offers a strategy to improve nuclear imaging and radiopharmaceutical therapy by increasing tumor-to-background activity concentration ratios and decreasing radiation burden to healthy tissues. One particularly promising approach to in vivo pretargeting is predicated on the inverse electron-demand Diels-Alder (IEDDA) ligation between tetrazine (Tz)-based radioligands and
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting. · full record | OpenQuestion